Skip to content
Search

Latest Stories

Moeen Ali aims to make up for lost time after virus bout

Moeen Ali has set his sights on making a big contribution to England's Test series in India after his comeback was delayed by the coronavirus.

Moeen took a break from Test cricket after being dropped during the 2019 Ashes series against Australia.


The all-rounder had hoped to feature in England's Tests in Sri Lanka earlier this month.

But rather than playing a part in a 2-0 series win, Moeen spent almost two weeks in isolation after testing positive for the virus on arrival in the country.

The 33-year-old, whose Test achievements include 181 wickets and nearly 3,000 runs, experienced three days of symptoms before spending time in self-isolation in a hotel.

He is currently back in quarantine alongside the rest of the squad in India, with everyone obliged to complete six days in their rooms and return three negative results before next week's first Test in Chennai.

"It has been tough but I'm a big believer in 'After hardship comes ease'. Hopefully there is some ease after this," Ali said.

"I feel good and I've been training normally for a while. When I got out for the first four or five days we had to be careful, because I think heart-rate can be an issue after Covid for people who do a bit of running.

"I have no match practice or anything but when we get out of here I'll train as hard as I can, spend time on my feet and try to be ready."

Reflecting on his initial experience of Covid-19, Moeen said: "I was not surprised because once I landed I didn't feel great.

"Part of me was thinking 'Let's get this over and done with, as long as it's not too bad'.

"I had loss of taste for a day or so, splitting headaches for three days, my body was very sore and I've never experienced that sort of tiredness before in my life. It was three days feeling pretty rough and the rest was fine.

"I didn't want the cough and fever and thankfully I didn't have that. There's part of you that's worried and anticipating it would be bad."

Having experienced the virus first-hand, Ali is backing the United Kingdom's vaccination programme at a time when there is a nervousness among some Muslim communities that the vaccine may be forbidden in Islamic Law.

"Having spoken to people who know quite a bit about it, I'd take it and get my family and others to take it," he said.

"It's like any vaccine, there's a lot of conspiracy theories out there but it's just medicine evolving.

"In our community people are sometimes not sure whether to take something -- a bit cautious -- but for things to get back to normal, it's important that we do it."

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less